Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3085% above fair value
$270.47+3.33 (+1.25%)
Close on Nov 20, 2026Market cap $651.11BP/E 41.0Yield 1.90%
Johnson & Johnson free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Johnson & Johnson's free cash flow for the twelve months ending Sep 27, 2026 was $20.59B, up 5.1% year over year. For fiscal 2025 it was $19.70B, down 0.7% from the year before. Over ten years it grew 2.0% a year on average. The highest annual figure on record is $20.19B in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $19.70B | -0.7% |
| FY2024 | Dec 29, 2024 | $19.84B | +8.7% |
| FY2023 | Dec 31, 2023 | $18.25B | +6.2% |
| FY2022 | Jan 1, 2023 | $17.19B | -13.0% |
| FY2021 | Jan 2, 2022 | $19.76B | -2.1% |
| FY2020 | Jan 3, 2021 | $20.19B | +1.4% |
| FY2019 | Dec 29, 2019 | $19.92B | +7.5% |
| FY2018 | Dec 30, 2018 | $18.53B | +4.2% |
| FY2017 | Dec 31, 2017 | $17.78B | +14.4% |
| FY2016 | Jan 1, 2017 | $15.54B | -3.5% |
| FY2015 | Jan 3, 2016 | $16.11B | +7.4% |
| FY2014 | Dec 28, 2014 | $15.00B | +8.5% |
| FY2013 | Dec 29, 2013 | $13.82B | +10.9% |
| FY2012 | Dec 30, 2012 | $12.46B | +9.3% |
| FY2011 | Jan 1, 2012 | $11.41B | -18.5% |
| FY2010 | Jan 2, 2011 | $14.00B | -1.4% |
| FY2009 | Jan 3, 2010 | $14.21B | +19.3% |
| FY2008 | Dec 28, 2008 | $11.91B | -1.4% |
| FY2007 | Dec 30, 2007 | $12.08B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $6.36B | -20.6% |
| Q2 FY2026 | Jun 28, 2026 | $7.30B | +157.3% |
| Q1 FY2026 | Mar 29, 2026 | $1.47B | -56.6% |
| Q4 FY2025 | Dec 28, 2025 | $5.47B | +1.9% |
| Q3 FY2025 | Sep 28, 2025 | $8.01B | +15.0% |
| Q2 FY2025 | Jun 29, 2025 | $2.84B | -39.1% |
| Q1 FY2025 | Mar 30, 2025 | $3.38B | +18.6% |
| Q4 FY2024 | Dec 29, 2024 | $5.37B | -14.4% |
| Q3 FY2024 | Sep 29, 2024 | $6.96B | +6.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.66B | +52.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.85B | +19.0% |
| Q4 FY2023 | Dec 31, 2023 | $6.27B | +66.7% |
| Q3 FY2023 | Oct 1, 2023 | $6.52B | +22.3% |
| Q2 FY2023 | Jul 2, 2023 | $3.06B | -35.2% |
| Q1 FY2023 | Apr 2, 2023 | $2.39B | -29.0% |
| Q4 FY2022 | Jan 1, 2023 | $3.76B | -12.8% |
| Q3 FY2022 | Oct 2, 2022 | $5.33B | -29.3% |
| Q2 FY2022 | Jul 3, 2022 | $4.72B | +4.8% |
| Q1 FY2022 | Apr 3, 2022 | $3.37B | -0.7% |
| Q4 FY2021 | Jan 2, 2022 | $4.32B | -38.5% |
| Q3 FY2021 | Oct 3, 2021 | $7.54B | -1.3% |
| Q2 FY2021 | Jul 4, 2021 | $4.50B | +61.3% |
| Q1 FY2021 | Apr 4, 2021 | $3.40B | +24.3% |
| Q4 FY2020 | Jan 3, 2021 | $7.02B | +36.6% |
| Q3 FY2020 | Sep 27, 2020 | $7.65B | +12.7% |
| Q2 FY2020 | Jun 28, 2020 | $2.79B | -45.4% |
| Q1 FY2020 | Mar 29, 2020 | $2.73B | -5.3% |
| Q4 FY2019 | Dec 29, 2019 | $5.14B | +4.3% |
| Q3 FY2019 | Sep 29, 2019 | $6.78B | +24.4% |
| Q2 FY2019 | Jun 30, 2019 | $5.11B | -1.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.89B | -2.1% |
| Q4 FY2018 | Dec 30, 2018 | $4.93B | +1.3% |
| Q3 FY2018 | Sep 30, 2018 | $5.45B | -0.4% |
| Q2 FY2018 | Jul 1, 2018 | $5.20B | +2.4% |
| Q1 FY2018 | Apr 1, 2018 | $2.95B | +25.3% |
| Q4 FY2017 | Dec 31, 2017 | $4.87B | -12.5% |
| Q3 FY2017 | Oct 1, 2017 | $5.48B | – |
| Q2 FY2017 | Jul 2, 2017 | $5.08B | – |
| Q1 FY2017 | Apr 2, 2017 | $2.35B | – |
| Q4 FY2016 | Jan 1, 2017 | $5.56B | – |
See a number that looks wrong?